daunorubicin

简明释义

英[ˌdɔːnəˈruːbɪsɪn]美[dɔːnəˈruːbɪsɪn]

n. 道诺霉素；红比霉素；正定霉素；柔毛霉素（用作抗肿瘤药）

英英释义

单词用法

同义词

反义词

例句

1.Objective: to investigate the diagnostic value of single photon emission computed tomography (SPECT) in early Daunorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia.

目的：探讨单光子断层显像(SPECT)对急性淋巴细胞白血病患儿应用柔红霉素后早期心肌毒性的诊断价值。

2.The inhibition rate on K562/A02 cell line of Pirarubicin group was significantly higher than that of the same dose of Pharmorubicin or Daunorubicin (P<0.01).

吡喃阿霉素组对K562/A02细胞的抑制率较相同剂量表阿霉素组或柔红霉素组抑制率显著增加（P<0.01）。

3.Objective: To determine the content of daunorubicin hydrochloride in its liposomes by HPLC.

目的：测定脂质体中盐酸柔红霉素的含量。

4.Objective: to investigate the diagnostic value of single photon emission computed tomography (SPECT) in early Daunorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia.

目的：探讨单光子断层显像(SPECT)对急性淋巴细胞白血病患儿应用柔红霉素后早期心肌毒性的诊断价值。

5.Objective To observe the protective effect of procaine and 654-2 on vein injury induced by daunorubicin.

目的观察普鲁卡因和654-2对柔红霉素静脉损伤的保护作用。

6.This class of agents includes doxorubicin, daunorubicin, and epirubicin, which are often used as adjuvant therapy in breast cancer.

这剂类包括阿霉素，柔红霉素，阿霉素和，这些问题往往在乳腺癌辅助疗法。

7.The oncologist prescribed daunorubicin for the treatment of acute myeloid leukemia.

肿瘤科医生为急性髓性白血病的治疗开了达诺鲁比辛。

8.Patients receiving daunorubicin should be monitored for potential heart complications.

接受达诺鲁比辛治疗的患者应监测潜在的心脏并发症。

9.In clinical trials, daunorubicin showed significant efficacy against certain types of cancer.

在临床试验中，达诺鲁比辛对某些类型的癌症显示出显著疗效。

10.The side effects of daunorubicin can include nausea and hair loss.

使用达诺鲁比辛的副作用可能包括恶心和脱发。

11.Combination therapy with daunorubicin and other agents may improve treatment outcomes.

与其他药物联合使用达诺鲁比辛可能改善治疗效果。

作文

Daunorubicin is a chemotherapy drug that is primarily used in the treatment of certain types of cancer, especially leukemia. This medication belongs to a class of drugs known as anthracyclines, which are derived from the bacterium Streptomyces peucetius. The mechanism of action of daunorubicin (达诺鲁比星) involves intercalating into DNA, thereby inhibiting the synthesis of nucleic acids and preventing cancer cells from dividing and growing. As a result, it is often prescribed for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The history of daunorubicin (达诺鲁比星) dates back to the early 1960s when it was first isolated. Since then, it has become a cornerstone in the treatment regimens for various cancers. Its effectiveness is well-documented, but like many chemotherapy agents, it comes with a range of side effects. Patients may experience nausea, vomiting, hair loss, and an increased risk of infection due to its impact on the bone marrow. One of the significant challenges in using daunorubicin (达诺鲁比星) is the potential for cardiotoxicity. Long-term use or high doses of this drug can lead to heart damage, which necessitates careful monitoring of cardiac function during treatment. Oncologists often perform echocardiograms before and during therapy to assess any changes in heart health. This concern has led to ongoing research aimed at finding ways to mitigate the risk of heart problems while still benefiting from the antitumor effects of daunorubicin (达诺鲁比星). In recent years, there have been advancements in drug formulations and delivery methods to improve the therapeutic index of daunorubicin (达诺鲁比星). For instance, liposomal formulations of the drug have been developed to enhance its efficacy and reduce toxicity. These innovations aim to deliver the drug more effectively to tumor sites while sparing healthy tissues, thus minimizing side effects. Furthermore, clinical trials continue to explore combinations of daunorubicin (达诺鲁比星) with other agents to enhance its effectiveness. Researchers are investigating how to integrate this drug with targeted therapies and immunotherapies, which may provide better outcomes for patients with resistant forms of leukemia. In conclusion, daunorubicin (达诺鲁比星) remains a vital component of cancer treatment, particularly for leukemia. While its benefits are substantial, the associated risks highlight the importance of personalized medicine in oncology. By tailoring treatment plans based on individual patient needs and responses, healthcare providers can maximize the therapeutic effects of daunorubicin (达诺鲁比星) while minimizing adverse effects. As research continues to evolve, the future of cancer treatment holds promise for improved strategies that incorporate this powerful drug with greater safety and efficacy.

达诺鲁比星是一种化疗药物，主要用于治疗某些类型的癌症，尤其是白血病。这种药物属于一种称为蒽环类药物的药物类别，这类药物来源于细菌Streptomyces peucetius。daunorubicin（达诺鲁比星）的作用机制涉及插入DNA，从而抑制核酸的合成，阻止癌细胞分裂和生长。因此，它通常被开处方给急性髓性白血病（AML）和急性淋巴细胞白血病（ALL）患者。daunorubicin（达诺鲁比星）的历史可以追溯到20世纪60年代，当时它首次被分离出来。从那时起，它成为各种癌症治疗方案中的基石。其有效性得到了充分证明，但与许多化疗药物一样，它也伴随着一系列副作用。患者可能会经历恶心、呕吐、脱发和由于对骨髓的影响而导致的感染风险增加。使用daunorubicin（达诺鲁比星）的一个重大挑战是潜在的心脏毒性。长期使用或高剂量使用这种药物可能导致心脏损伤，这就需要在治疗过程中仔细监测心功能。肿瘤科医生通常会在治疗前和治疗期间进行超声心动图，以评估心脏健康的变化。这一问题促使了持续的研究，旨在寻找减轻心脏问题风险的方法，同时仍能从daunorubicin（达诺鲁比星）的抗肿瘤效果中获益。近年来，药物配方和给药方法的进展改善了daunorubicin（达诺鲁比星）的治疗指数。例如，已经开发出脂质体配方的药物，以增强其疗效并减少毒性。这些创新旨在更有效地将药物输送到肿瘤部位，同时保护健康组织，从而最小化副作用。此外，临床试验继续探索将daunorubicin（达诺鲁比星）与其他药物结合使用以增强其有效性。研究人员正在调查如何将这种药物与靶向疗法和免疫疗法结合，这可能为耐药性白血病患者提供更好的结果。总之，daunorubicin（达诺鲁比星）仍然是癌症治疗的重要组成部分，特别是对白血病患者而言。尽管其益处巨大，但相关风险突显了个性化医学在肿瘤学中的重要性。通过根据个体患者的需求和反应量身定制治疗计划，医疗提供者可以最大化daunorubicin（达诺鲁比星）的治疗效果，同时最小化不良反应。随着研究的不断发展，癌症治疗的未来承诺将改善将这种强效药物与更高安全性和有效性的策略结合起来。